Compositions and methods targeting the nucleotide free state of ras to block oncogenic signaling and transformation
US-2022324998-A1 · Oct 13, 2022 · US
Compositions and methods targeting the nucleotide free state of RAS to block oncogenic signaling and transformation
US12565537B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12565537-B2 |
| Application number | US-202017620395-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 18, 2020 |
| Priority date | Jun 18, 2019 |
| Publication date | Mar 3, 2026 |
| Grant date | Mar 3, 2026 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides compositions and methods for binding Ras in a nucleotide free state (apo RAS) and inhibiting Ras signaling. In one embodiment, the invention provides monobodies that specifically bind apo RAS and methods of use. Thus, in diseases and conditions where a reduction of Ras signaling is beneficial, such inhibitory compositions act as therapeutics.
First claim
Opening claim text (preview).
What is claimed is: 1 . A composition comprising at least one molecule comprising a monobody domain that selectively binds RAS in a nucleotide free state (apo RAS) but not RAS in the nucleotide-bound state, wherein the monobody domain comprises a sequence selected from the group consisting of SEQ ID NO: 1-6. 2 . The composition of claim 1 , wherein the composition further comprises a fusion protein fused to the monobody domain or a peptide comprising the monobody domain. 3 . The composition of claim 2 , wherein the fusion protein comprising a monobody domain further comprises a therapeutic agent or a detection moiety. 4 . An isolated nucleic acid molecule encoding the molecule of claim 1 that selectively binds apo RAS but does not bind to nucleotide-bound RAS. 5 . An expression vector comprising the nucleic acid molecule of claim 4 . 6 . A host cell comprising the nucleic acid molecule of claim 4 .
Assignees
Inventors
Classifications
involving oncogenic proteins · CPC title
Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A) · CPC title
Hydrolases (3) · CPC title
Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto · CPC title
Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12565537B2 cover?
- The invention provides compositions and methods for binding Ras in a nucleotide free state (apo RAS) and inhibiting Ras signaling. In one embodiment, the invention provides monobodies that specifically bind apo RAS and methods of use. Thus, in diseases and conditions where a reduction of Ras signaling is beneficial, such inhibitory compositions act as therapeutics.
- Who is the assignee on this patent?
- Musc Found For Res Dev, Univ New York, Us Gov Veterans Affairs
- What technology area does this patent fall under?
- Primary CPC classification C07K16/32. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 03 2026 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).